Pharvaris Completes Enrollment in Pivotal HAE Study, Topline Data Expected in Q3
PHVS has more than doubled off its 52-week low of $11.51 on elevated volume (2.9× avg).
Summary
Pharvaris N.V. has announced the completion of enrollment in its CHAPTER-3 pivotal study for Deucrictibant XR, a prophylactic treatment for Hereditary Angioedema (HAE) attacks. This milestone signifies the successful progression of a key clinical trial for the company's lead candidate. The completion of enrollment de-risks the trial execution phase and provides a clear path towards regulatory submission. Investors should now anticipate topline data from this crucial study in the third quarter of this year, which will be a major catalyst for the stock.
At the time of this announcement, PHVS was trading at $27.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $11.51 to $29.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.